Filing Details

Accession Number:
0000947871-24-001018
Form Type:
13G Filing
Publication Date:
2024-12-17 19:00:00
Filed By:
Qatar Investment Authority
Company:
Bioxcel Therapeutics Inc. (NASDAQ:BTAI)
Filing Date:
2024-12-18
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Qatar Investment Authority 0 2,724,075 5.20%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  The numbers in rows 5, 7 and 9 represent 2,724,075 shares of Common Stock issuable to Q Boost Holding LLC, the Reporting Person's wholly-owned subsidiary (the "Subsidiary"), upon exercise of the Issuer warrant held by the Subsidiary. The percentage of class in row 11 is calculated assuming 52,353,023 shares of common stock per share (the "Common Stock") are outstanding based on (i) 49,628,948 shares of Common Stock outstanding as of December 17, 2024 (such outstanding shares based on information provided to the Reporting Persons by the Issuer) and (ii) 2,724,075 shares of Common Stock issuable to the Subsidiary upon exercise of the Issuer warrant held by the Subsidiary.


SCHEDULE 13G


 
Qatar Investment Authority
 
Signature:/s/ Andrew Watkins
Name/Title:Andrew Watkins**/Associate General Counsel, Head of Compliance
Date:12/18/2024

Comments accompanying signature:  **Evidence of authority to sign on behalf of Qatar Investment Authority is set forth in a Certificate of Incumbency, dated February 02, 2022, and included as Exhibit 99.2 hereto.
Exhibit Information

Exhibit No. Description 99.1 Item 7 Information 99.2 Certificate of Incumbency